Pharma Hot Topics Blog

Every market evaluates drugs based on price and patient outcome these days. In Japan, the government is encouraging the use of generic drugs as it sees generics cost less and are still effective. It seems the Japanese government sees generic drugs as a primary way to reduce costs, and is encouraging their use. As a result, generics are increasing market penetration and expected to be around 70% by mid 2017 and around 80% by mid 2018 or 2020. What does this mean for the Pharmaceutical industry?

Read More >>

Beyond the Pipeline – where do we go next?

While many articles are examining the industry pipeline and while investors are pleased with what they see, this has not diminished the discussion about poor innovation in the industry and the lack of productivity in R&D. It is an oft-discussed topic and one that is understandable. Part of the problem is that making important strides forward is difficult with classic scientific methods where one must isolate one variable at a time in a complex, multi-faceted, physiological environment.

Read More >>

AI’s Impact on the Changes in Pharma Marketing

A couple of years ago, a Harris Interactive survey found that 9 out of 10 Americans believed Pharma companies to be dishonest. The negative news continues to paint Pharma in a tarnished light while executives scramble to repair the damage. At the same time, decreasing profit margins, and the changes in the way healthcare is delivered, forces an industry-wide assessment of how to adapt to the new world of healthcare.

Read More >>

The Shocking Truth About Clinical Superiority

Let’s face it; there are a lot of competing products with little to really tell them apart. This raises the question of what’s more important for long-term commercial success – being first to market or being best clinically.

Read More >>

Despite the lack of access to Twitter, Facebook or YouTube, social media in China is thriving. Here’s how you should respond.

Read More >>

Too many pharma marketers are ignoring the powerful data at their fingertips. Is it any wonder that so many once-top brands are losing market share?

Read More >>

Pharmaceutical companies can no longer ignore the hidden value available by increasing patient adherence.

Read More >>

Patients, physicians and other stakeholders are interacting with brands before they ever use them. Because of brands such as Apple, Google or Amazon, buyers expect to interact with more user‐centered offerings that meet their everyday needs and require limited technical involvement, even though the core users of that offering will often not be those making the purchasing decision around that offering.

Read More >>

© 2014 Eularis